European regulatory authorities have finalized an assessment of reported non-compliance with GMP at Ranbaxy Labs’ manufacturing site in Toansa, India. While the assessment showed a number of GMP deficiencies at the site, European regulators concluded that there has been no risk to public health from these deficiencies. European regulators reviewed the corrective measures put in place by the company and found them to be sufficient to ensure GMP compliance, and, as a result, will reinstate the GMP...